mdl-201112 has been researched along with Alloxan Diabetes in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Holstad, M; Sandler, S; Thorvaldson, L | 1 |
| Holstad, M; Sandler, S | 1 |
2 other study(ies) available for mdl-201112 and Alloxan Diabetes
| Article | Year |
|---|---|
Cytokine release by murine spleen cells following multiple low dose streptozotocin-induced diabetes and treatment with a TNFalpha transcriptional inhibitor.
Topics: Adenine; Animals; Blood Glucose; Carboxymethylcellulose Sodium; Cells, Cultured; Concanavalin A; Cytokines; Diabetes Mellitus, Experimental; Interferon-gamma; Interleukin-10; Male; Mice; Mice, Inbred C57BL; Spleen; Tumor Necrosis Factor-alpha | 2003 |
A transcriptional inhibitor of TNF-alpha prevents diabetes induced by multiple low-dose streptozotocin injections in mice.
Topics: Adenine; Animals; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Injections; Male; Mice; Mice, Inbred C57BL; RNA, Messenger; Streptozocin; Transcription, Genetic; Tumor Necrosis Factor-alpha | 2001 |